The Food and Drug Administration (FDA) has approved a 10mg/mL solution for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 mutations….
Everything about lung cancer is here.
The Food and Drug Administration (FDA) has approved a 10mg/mL solution for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 mutations….